Danaher Corp.

What happened / headline results (2Q26 beat) - Danaher delivered $6.3B sales in Q2 2026; core revenue +3% YoY and core growth (ex-respiratory) +4.5% YoY, an acceleration of ~150 bps vs Q1. - Adjusted EPS: $1.94, ~+8% YoY (high single-digit earnings growth). - Margins & cash: 57.6% gross margin; adjusted op margin 27.1% (-20 bps YoY, mainly due to respiratory mix), $1.3B free cash flow in the quarter; $2.4B in 1H and 124% FCF-to-net income conversion YTD. - Surprising/positive: strong performance in life sciences—described as their strongest quarter in several years—plus better-than-expected results overall.

Key segment drivers (good + ongoing challenges) - Diagnostics: core revenue +2%; core growth ex-respiratory +5%; Leica/Radiometer high single digits, Beckman mid-single digits, Cepheid low double-digit non-respiratory (GI + sexual health + hospital-acquired infection). - Biotechnology: core revenue +2.5% overall; order trends strong (mid-teens orders growth in consumables & equipment). - Main negative/challenge: bioprocessing revenue came in low single digits due to shipment timing—not a demand collapse—especially chromatography resin shipments delayed at customers’ request (site readiness / production schedule).

The big question: why bioprocessing revenue didn’t “catch up” immediately - Management explained Q2 consumables were lighter than expected because a few $10M–$30M shipments slated for Q2/Q3 moved out (customer-driven timing). - Quantification (CFO): the timing shift created roughly ~500 bps impact to Q2 bioprocessing growth, and for the full year management indicated “a little north of $100M” shifted out of Q2/Q3 into next year (with some chance of movement into Q4, but not assumed in planning). - Risk framing (investor-relevant): while underlying orders remain healthy and management sees inventory dynamics improving, revenue visibility can still swing quarter-to-quarter when shipment timing concentrates in a few customers.